<DOC>
	<DOCNO>NCT00946478</DOCNO>
	<brief_summary>The purpose study determine effect topical pimecrolimus immune system assess level antimicrobial peptide skin patient eczema . It hypothesize pimecrolimus apply topically repair body 's immune system patient eczema increase antimicrobial peptide .</brief_summary>
	<brief_title>Effect Pimecrolimus Cream Cathelicidin Levels Subjects With Eczema</brief_title>
	<detailed_description>Patients atopic dermatitis ( AD ) high rate skin infection virus bacteria . They also impair innate immune system . Antimicrobial peptides component innate immune system decrease atopics . In vitro , pimecrolimus demonstrate ability increase antimicrobial peptide . This study examine ability pimecrolimus increase antimicrobial peptide vivo AD patient . Thus , study yield well understanding role pimecrolimus regulate immune system atopics .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>1 . Age 1870 year 2 . Target lesion IGA ≥2 3 . Target IGA=0 ( nonlesional site ) 4 . Male female race ethnicity 5 . Chronic AD one year duration 6 . Subject childbearing potential must willing practice effective birth control study 7 . Subject agree comply study requirement attend require visit . 1 . Patients ≥ 18 year age AD face 2 . Women childbearing potential use contraception method ( ) specify study ( abstinence , IUD , diaphragm , oral contraceptive ) 3 . Patients severe medical condition ( ) view investigator prohibit participation study 4 . Hypersensitivity pimecrolimus cream excipient cream 5 . Subject skin disorder addition dermatitis area treat 6 . Subject Netherton 's syndrome genodermatoses result defective epidermal barrier 7 . Pregnant nursing female 8 . Immunocompromised patient ( e.g. , lymphoma , HIV/AIDS , WiskottAldrich Syndrome ) , history active malignant disease ( exclude nonmelanoma skin cancer ) 9 . History psychiatric disease history alcohol drug abuse would interfere ability comply study protocol 10 . Patients know noncompliant medication regimen 11 . Subjects significant concurrent medical condition ( ) screen view investigator prohibit participation study ( e.g. , severe concurrent allergic disease , condition associate malignancy , condition associate immunosuppression ) 12 . Active viral fungal skin infection target area 13 . Previous participation study 14 . Ongoing participation another investigational trial 15 . Use oral topical antibiotic study one week prior enter study 16 . Use local therapy AD le one week prior screen 17 . Use systemic immunosuppressive therapy AD le four week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>atopic dermatitis</keyword>
	<keyword>elidel</keyword>
	<keyword>pimecrolimus</keyword>
	<keyword>CASM981</keyword>
	<keyword>immunity</keyword>
	<keyword>cathelicidin</keyword>
	<keyword>antimicrobial peptide</keyword>
	<keyword>eczema</keyword>
</DOC>